pegylated liposomal doxorubicin + carboplatin + trastuzumab

Pegylated liposomal doxorubicin + carboplatin + trastuzumab is a combination cancer therapy specifically used for human epidermal growth factor receptor-2 (HER2)-positive cancers, including ovarian and breast cancer. **Pegylated liposomal doxorubicin** is a reformulated doxorubicin encapsulated in PEG-coated liposomes, which prolongs circulation time and enhances tumor selectivity due to the enhanced permeation and retention effect. It functions as a cytotoxic anthracycline, inhibiting topoisomerase II and thereby blocking DNA replication and repair. **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA cross-linking and apoptosis in tumor cells. **Trastuzumab** is a monoclonal antibody that targets HER2 (human epidermal growth factor receptor 2), blocking downstream signaling pathways, and promoting antibody-dependent cellular cytotoxicity. This combination is used for HER2-positive patients who may benefit from multi-agent chemotherapy with targeted and cytotoxic mechanisms. Most studied in ovarian and breast cancers, this regimen aims to maximize antitumor activity while minimizing cardiotoxicity and other adverse events by using liposomal doxorubicin instead of conventional anthracyclines[1][2][3][4][5][6][7].